Context Therapeutics Inc.: Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76
CTIM-76 Phase 1 trial focused on CLDN6-positive gynecologic and testicular cancers Trial marks key milestone in driving pipeline progress PHILADELPHIA, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Context Therap ...
Context doses first patient in Phase 1 clinical trial evaluating CTIM-76
Context Therapeutics (CNTX) announced that the first patient has been dosed in its Phase 1 clinical trial evaluating CTIM-76, a Claudin 6, or ...
Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors
Mr. Pasternak brings decades of global pharmaceutical leadership experienceTransition further highlights transformation of the Board to lead ...